Gyre Therapeutics (GYRE) Exchange Rate Effect (2023 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Exchange Rate Effect of $285000.0 for Q1 2026, up 470.0% year-over-year from $50000.0 in Q1 2025, and up 124.41% quarter-over-quarter from $127000.0 in Q4 2025.
Gyre Therapeutics (GYRE) Exchange Rate Effect (2023 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Exchange Rate Effect for 4 consecutive years, with $285000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Exchange Rate Effect rose 470.0% year-over-year to $285000.0; the TTM figure through Mar 2026 stood at $578000.0 (up 426.55% YoY), while the FY2025 annual figure was $343000.0, up 225.64% from the prior year.
- Exchange Rate Effect advanced to $285000.0 in Q1 2026 per GYRE's latest filing, from $127000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $285000.0 in Q1 2026 and bottomed at -$900000.0 in Q2 2023.
- Historically, Exchange Rate Effect has averaged $4384.6 across 4 years, with a median of $106000.0 in 2024.
- Annual changes were most pronounced in 2024 — Exchange Rate Effect plunged 210.39% — and 2026, when it soared 470.0%.
- Gyre Therapeutics' Exchange Rate Effect stood at $231000.0 in 2023, then slumped by 210.39% to -$255000.0 in 2024, then jumped by 149.8% to $127000.0 in 2025, then jumped by 124.41% to $285000.0 in 2026.
- Business Quant data shows GYRE's Exchange Rate Effect at $285000.0 in Q1 2026, $127000.0 in Q4 2025, and $117000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | 643,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 643,000.00 |
| Jun 30, 2026 | 643,000.00 |
| Mar 31, 2026 | 285,000.00 |
| Mar 31, 2026 | 285,000.00 |
| Dec 31, 2025 | 127,000.00 |
| Dec 31, 2025 | 127,000.00 |
| Sep 30, 2025 | 117,000.00 |
| Sep 30, 2025 | 117,000.00 |
| Jun 30, 2025 | 49,000.00 |
| Jun 30, 2025 | 49,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | -255,000.00 |
| Dec 31, 2024 | -255,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Jun 30, 2024 | -78,000.00 |
| Jun 30, 2024 | -78,000.00 |
| Mar 31, 2024 | -46,000.00 |
| Mar 31, 2024 | -46,000.00 |